Stockreport

Krystal Biotech Announces Fourth Quarter and Full Year 2025 Financial and Operating Results

Krystal Biotech, Inc.  (KRYS) 
Last krystal biotech, inc. earnings: 11/4 08:00 am Check Earnings Report
US:NASDAQ Investor Relations: ir.krystalbio.com/investors
PDF $107.1 million in 4Q VYJUVEK revenue and $730.3 million since U.S. launch FDA granted RMAT to KB707 for the treatment of advanced NSCLC and Fast Track Designation to KB [Read more]